TY - JOUR
T1 - Herbal and dietary supplement-induced liver injury in Taiwan
T2 - comparison with conventional drug-induced liver injury
AU - Huang, Yi Shin
AU - Chang, Ting Tsung
AU - Peng, Cheng Yuan
AU - Lo, Gin Ho
AU - Hsu, Chao Wei
AU - Hu, Chi Tan
AU - Huang, Yi Hsiang
N1 - Funding Information:
The study was supported by the Grants from Taiwan Food and Drug Administration (TFDA), Ministry of Health and Welfare, Taiwan (DOH100-99TFDA-P-092 and DOH101-FDA-41103), and Taipei Veterans General Hospital, Taiwan (V110C-022).
Publisher Copyright:
© 2021, Asian Pacific Association for the Study of the Liver.
PY - 2021/12
Y1 - 2021/12
N2 - Background and aims: Whether herbal and dietary supplements (HDS) are safer than Western conventional drugs is controversial. The aim of this study was to explore the characteristics and risk factors for HDS-induced liver injury (HILI) in Taiwan. Methods: This is a 9-year multi-center prospective study conducted in Taiwan from 2011 to 2019. Patients with HILI were compared to those with conventional drug-induced liver injury (CILI). Results: A total of 1,297 patients were enrolled, of whom 285 (22.0%) had HILI and 1,012 (78.0%) had CILI. Compared to the CILI group, the HILI group had higher initial serum alanine aminotransferase, alkaline phosphatase (ALP), peak ALP and bilirubin levels, and higher rates of jaundice, ascites, encephalopathy, coagulopathy, sepsis and acute liver failure. In addition, the HILI group had a higher mortality rate than the CILI group (12.6 vs. 8.0%, p = 0.016). Hepatitis B carrier status, elevated baseline liver biochemical tests and the use of crude herbs (without processing) were associated with an increased risk of HILI-related mortality (adjusted hazard ratios [95% confidence intervals]: 2.90 [1.43–5.99], 2.40 [1.01–5.68] and 2.94 [1.45–5.97], respectively). Conclusions: HDS are popular and incriminated in more than one-fifth of drug-induced liver injuries in Taiwan. The patients with HILI were more severe than those with CILI in terms of liver biochemical tests, complications and mortality. Hepatitis B carriers, those with elevated baseline liver tests and crude herb users may have a higher risk of HILI-related mortality. The prudent use of HDS is suggested in these high-risk subjects.
AB - Background and aims: Whether herbal and dietary supplements (HDS) are safer than Western conventional drugs is controversial. The aim of this study was to explore the characteristics and risk factors for HDS-induced liver injury (HILI) in Taiwan. Methods: This is a 9-year multi-center prospective study conducted in Taiwan from 2011 to 2019. Patients with HILI were compared to those with conventional drug-induced liver injury (CILI). Results: A total of 1,297 patients were enrolled, of whom 285 (22.0%) had HILI and 1,012 (78.0%) had CILI. Compared to the CILI group, the HILI group had higher initial serum alanine aminotransferase, alkaline phosphatase (ALP), peak ALP and bilirubin levels, and higher rates of jaundice, ascites, encephalopathy, coagulopathy, sepsis and acute liver failure. In addition, the HILI group had a higher mortality rate than the CILI group (12.6 vs. 8.0%, p = 0.016). Hepatitis B carrier status, elevated baseline liver biochemical tests and the use of crude herbs (without processing) were associated with an increased risk of HILI-related mortality (adjusted hazard ratios [95% confidence intervals]: 2.90 [1.43–5.99], 2.40 [1.01–5.68] and 2.94 [1.45–5.97], respectively). Conclusions: HDS are popular and incriminated in more than one-fifth of drug-induced liver injuries in Taiwan. The patients with HILI were more severe than those with CILI in terms of liver biochemical tests, complications and mortality. Hepatitis B carriers, those with elevated baseline liver tests and crude herb users may have a higher risk of HILI-related mortality. The prudent use of HDS is suggested in these high-risk subjects.
UR - http://www.scopus.com/inward/record.url?scp=85112297951&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112297951&partnerID=8YFLogxK
U2 - 10.1007/s12072-021-10241-3
DO - 10.1007/s12072-021-10241-3
M3 - Article
C2 - 34382132
AN - SCOPUS:85112297951
SN - 1936-0533
VL - 15
SP - 1456
EP - 1465
JO - Hepatology International
JF - Hepatology International
IS - 6
ER -